https://www.selleckchem.com/pr....oducts/ap-3-a4-enobl
y suggests that LMWH might reduce the risk of in-hospital mortality and severe ARDS in coronavirus disease 2019. Randomized controlled trials are warranted to confirm these preliminary findings.Short-course glucocorticosteroids are being used and tocilizumab (TCZ) had been used to treat patients with severe coronavirus disease 2019 (COVID-19) disease. These agents, when administered individually, have been associated with tuberculosis (T during chronic use. We report a case of TB in a 44-year-old male with diabetes and severe
Like
Comment
Share
